Invesco Nasdaq Biotechnology ETF (IBBQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Invesco Nasdaq Biotechnology ETF (IBBQ) trades at $35.80 with AI Score 47/100 (Grade C). The Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund that aims to replicate the performance of the Nasdaq Biotechnology… Market cap: $84.8M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for IBBQ: IBBQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IBBQ against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IBBQ: 1/3 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Invesco Nasdaq Biotechnology ETF (IBBQ) Financial Services Profile
The Invesco Nasdaq Biotechnology ETF (IBBQ) provides investors with targeted exposure to the biotechnology sector by tracking the Nasdaq Biotechnology Index, which includes a diverse range of publicly traded biotech and pharmaceutical companies, mitigating single-stock risk.
What Is the Investment Thesis for IBBQ?
The Invesco Nasdaq Biotechnology ETF (IBBQ) is strategically positioned to capitalize on the growth of the biotechnology sector, which is expected to expand significantly in the coming years. The ETF's focus on the Nasdaq Biotechnology Index allows it to benefit from the performance of leading biotech and pharmaceutical companies, many of which are at the forefront of medical innovation. With a market cap of $84.8M, IBBQ's diversified portfolio mitigates risks associated with individual stocks, which is crucial given the sector's susceptibility to volatility stemming from clinical trial outcomes and regulatory changes. The ongoing advancements in biotechnology, particularly in areas such as gene therapy and personalized medicine, are anticipated to drive growth in the sector. As the demand for innovative healthcare solutions increases, IBBQ is well-positioned to deliver value to investors through its exposure to high-growth companies. However, investors should remain aware of the inherent risks in the sector, including regulatory hurdles and market fluctuations, which could impact the ETF's performance.
Based on FMP financials and quantitative analysis
IBBQ Key Highlights
Market capitalization of $84.8M, indicating a focused investment strategy in biotechnology.
- Beta of 0.63, suggesting lower volatility compared to the broader market.
- No dividend yield, as the fund reinvests capital to track index performance.
- Tracks the Nasdaq Biotechnology Index, providing exposure to top biotech firms.
- Annual review and quarterly adjustments ensure alignment with market dynamics.
Who Are IBBQ's Competitors?
IBBQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IBB iShares Biotechnology ETF | $210.83 | -2.83% | $10.4B | 47 |
| XBI State Street SPDR S&P Biotech ETF | $166.49 | +1.90% | $8.70B | 47 |
| FBT First Trust NYSE Arca Biotechnology Index Fund | $267.87 | -1.47% | $1.67B | 47 |
| VHT Vanguard Health Care ETF | $323.69 | -1.76% | $21.7B | 46 |
| PBE Invesco Biotechnology & Genome ETF | $96.60 | -1.69% | $295M | 47 |
| AGNG Global X - Aging Population ETF | $38.75 | -1.11% | $88.2M | 47 |
| GESIX Lazard Global Equity Select Portfolio Institutional Shares | $19.17 | -0.14% | $79.9M | 52 |
| GESOX Lazard Global Equity Select Portfolio Open Shares | $19.13 | -0.10% | $79.9M | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IBBQ's Key Strengths?
Strong alignment with the Nasdaq Biotechnology Index, providing credibility.
- Diversified portfolio reduces risk associated with individual stocks.
- Regular adjustments to holdings enhance responsiveness to market dynamics.
- Established reputation as a reliable ETF in the biotechnology sector.
What Are IBBQ's Weaknesses?
No dividend yield may deter income-focused investors.
- Limited to biotechnology, which may restrict growth compared to broader sectors.
- Market cap of $84.8M may limit investor interest.
- Exposure to volatility inherent in the biotechnology sector.
What Could Drive IBBQ Stock Higher?
Annual review and update of the Nasdaq Biotechnology Index in December.
- Quarterly adjustments to the ETF's weightings in March, June, September, and December.
- Increasing investment in biotechnology research and development.
- Potential breakthroughs in gene therapy and personalized medicine.
- Continued demand for innovative healthcare solutions amid global health challenges.
What Are the Key Risks for IBBQ?
Regulatory changes impacting biotech firms could affect ETF performance.
- Market volatility in the biotechnology sector may lead to fluctuations in fund value.
- Competition from other ETFs could limit IBBQ's growth potential.
- Economic downturns may lead to reduced investments in biotechnology.
What Are the Growth Opportunities for IBBQ?
- Growth opportunity 1: The increasing demand for personalized medicine is expected to drive significant growth within the biotechnology sector. IBBQ's focus on companies innovating in this space positions it well to benefit from this trend.
- Growth opportunity 2: Advances in gene therapy are revolutionizing treatment options for various diseases, including genetic disorders and certain types of cancer. IBBQ's holdings in biotech firms engaged in gene therapy research provide a strategic advantage.
- Growth opportunity 3: The expansion of biopharmaceuticals is another key driver for the biotechnology sector.
- Growth opportunity 4: Increased government and private sector funding for biotech research is expected to enhance growth prospects for the industry. With funding levels projected to rise, IBBQ's exposure to companies benefitting from these investments positions it favorably for future growth.
- Growth opportunity 5: The ongoing COVID-19 pandemic has accelerated the development and approval of vaccines and therapeutics, leading to a heightened focus on biotechnology.
What Are IBBQ's Competitive Advantages?
- Diversified exposure to a wide range of biotechnology companies reduces risk.
- The ETF's alignment with the Nasdaq Biotechnology Index enhances credibility.
- Regular index reviews and adjustments ensure responsiveness to market changes.
- IBBQ's focus on leading biotech firms positions it favorably in the sector.
- The fund's structure allows for liquidity and ease of trading.
What Does IBBQ Do?
The Invesco Nasdaq Biotechnology ETF (IBBQ) was established to provide investors with a straightforward way to gain exposure to the biotechnology sector, which is characterized by rapid innovation and significant growth potential. The fund seeks to mirror the investment performance of the Nasdaq Biotechnology Index, which comprises biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market. To achieve its investment objective, the ETF allocates at least 90% of its total capital to the securities within this benchmark index, ensuring that it closely tracks the performance of the underlying assets. The Index itself undergoes an annual review and update in December, with quarterly adjustments to its weightings occurring in March, June, September, and December. This systematic approach to index management allows for a responsive investment strategy that adapts to market conditions. As a result, IBBQ has positioned itself as a key player in the asset management space, particularly within the biotechnology sector, which is known for its volatility and potential for high returns. The ETF's diversified holdings help mitigate risks associated with individual stocks, making it an appealing choice for investors looking to participate in the biotech market without being overly exposed to the performance of any single company.
What Products and Services Does IBBQ Offer?
- IBBQ is an exchange-traded fund that tracks the Nasdaq Biotechnology Index.
- The fund invests at least 90% of its total capital in securities that comprise the index.
- It provides investors with diversified exposure to the biotechnology and pharmaceutical sectors.
- IBBQ undergoes an annual review and quarterly adjustments to ensure alignment with market trends.
- The ETF aims to mirror the investment performance of its benchmark index.
- It is designed for investors looking to mitigate single-stock risk in the biotech sector.
How Does IBBQ Make Money?
- IBBQ generates revenue through management fees charged to investors.
- The fund's performance is linked to the returns of the Nasdaq Biotechnology Index.
- It aims to provide capital appreciation through strategic investments in biotech firms.
- The ETF does not pay dividends, focusing on reinvestment for growth.
- IBBQ's structure allows for efficient trading on stock exchanges.
What Industry Does IBBQ Operate In?
The biotechnology sector has been experiencing robust growth, driven by increased investment in research and development, advancements in technology, and a rising demand for innovative healthcare solutions. Within this landscape, IBBQ serves as a crucial vehicle for investors seeking exposure to a diversified portfolio of biotechnology and pharmaceutical companies. The competitive landscape includes various ETFs and mutual funds that also target the biotech sector, but IBBQ's focus on the Nasdaq index provides a unique positioning that emphasizes leading firms in the industry.
Who Are IBBQ's Key Customers?
- Institutional investors seeking exposure to the biotechnology sector.
- Retail investors looking for diversified investment options in biotech.
- Financial advisors recommending biotech investments to clients.
- Pension funds and endowments interested in long-term growth strategies.
- Wealth management firms incorporating ETFs into client portfolios.
Invesco Nasdaq Biotechnology ETF (IBBQ) Valuation Context
Valued at $84.8M, IBBQ is classified as a micro-cap stock. Relative to its peer group, IBBQ's quantitative score of 47/100 is roughly in line with the peer average of 47/100.
Key Financial Metrics
Return on equity for Invesco Nasdaq Biotechnology ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. IBBQ trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
IBBQ Financials
Bull Case vs Bear Case
Bull Case
- Strong alignment with the Nasdaq Biotechnology Index, providing credibility.
- Diversified portfolio reduces risk associated with individual stocks.
- Regular adjustments to holdings enhance responsiveness to market dynamics.
- Established reputation as a reliable ETF in the biotechnology sector.
Bear Case
- No dividend yield may deter income-focused investors.
- Limited to biotechnology, which may restrict growth compared to broader sectors.
- Market cap of $84.8M may limit investor interest.
- Exposure to volatility inherent in the biotechnology sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
IBBQ Latest News
No recent news available for IBBQ.
IBBQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IBBQ.
Price Targets
Wall Street price target analysis for IBBQ.
IBBQ MoonshotScore
What does this score mean?
The MoonshotScore rates IBBQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
IBBQ Financial Services Stock FAQ
What does the AI Score mean for IBBQ?
IBBQ holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. The Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund that aims to replicate the performance of the Nasdaq Biotechnology Index, focusing on biotechnology and pharmaceutical …
What does Invesco Nasdaq Biotechnology ETF do?
The Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund that aims to replicate the performance of the Nasdaq Biotechnology Index. It invests at least 90% of its total capital in the securities that comprise this index, focusing on biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market.
What do analysts say about IBBQ stock?
Analysts generally view IBBQ as a solid investment vehicle for gaining exposure to the biotechnology sector. They highlight its diversified portfolio and alignment with the Nasdaq Biotechnology Index, which includes leading biotech firms. Analysts often emphasize the ETF's potential for capital appreciation, although they caution about the inherent volatility in the biotech industry.
What are the main risks for IBBQ?
IBBQ faces several risks, including regulatory changes that could impact the performance of its underlying biotech holdings. The biotechnology sector is known for its volatility, which can lead to significant fluctuations in the ETF's value. Additionally, competition from other ETFs targeting the biotech space may limit IBBQ's market share and growth potential.
What are the key factors to evaluate for IBBQ?
Invesco Nasdaq Biotechnology ETF (IBBQ) holds an AI score of 47/100 (low). The Invesco Nasdaq Biotechnology ETF (IBBQ) is strategically positioned to capitalize on the growth of the biotechnology sector, which is expected to expand significantly in the coming years. Not financial advice.
How frequently does IBBQ data refresh on this page?
IBBQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IBBQ's recent stock price performance?
Invesco Nasdaq Biotechnology ETF (IBBQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong alignment with the Nasdaq Biotechnology Index, providing credibility. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IBBQ overvalued or undervalued right now?
Invesco Nasdaq Biotechnology ETF (IBBQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IBBQ before investing?
Before investing in Invesco Nasdaq Biotechnology ETF (IBBQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on current market conditions and may be subject to change.